リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment

廣岡 靖章 近畿大学

2022.03.01

概要

Introduction:
Osteoporosis is one of the serious adverse effects associated with glucocorticoid therapy. Although bisphosphonates have been used for glucocorticoid-induced osteoporosis (GIO), some patients have shown an inadequate response. In such cases, denosumab or teriparatide are used. However, there is no consensus on which of these two drugs is superior. We prospectively compared denosumab's and teriparatide's effects on the bone mineral density (BMD) in GIO patients with prior bisphosphonate treatment.

Materials and methods:
After receiving oral bisphosphonates for ≥2 years, GIO patients with low T-score BMD(< -2.5) were switched from bisphosphonates to denosumab (n = 20) or daily teriparatide (n = 21). Wemeasured the BMD (lumbar spine, femoral neck, and total hip) in both groups every 6 months for 24 months.

Results:
At 24 months of treatment, the lumbar spine BMD increased significantly from baseline in both the denosumab and teriparatide groups (baseline vs. denosumab and teriparatide; 5.9 ‡ 5.6%, P < 0.001 and 7.9 ‡ 5.4%, P < 0.001). A significant increase in femoral neck BMD from baseline occurred only in the teriparatide group (6.6 ‡ 10.8%, P < 0.05); denosumab (1.5 ‡ 5.0%). No significant changes occurred in the total hip BMD from baseline in either group (-0.1 ‡ 5.6% and 3.3 ‡ 7.5%, respectively). There was no significant difference between the denosumab and teriparatide groups at 24 months in lumbar spine and femoral neck BMD, but was significantly higher in the teriparatide group at 12 months (P < 0.01 and P < 0.05 in the lumbar spine and femoral neck, respectively).

Conclusion:
Teriparatide might have some advantages over denosumab and be a good alternative for treating GIO patients with prior bisphosphonate treatment.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

Angeli, A., Guglielmi, G., Dovio, A., Capelli, G., de Feo, D., Giannini, S., Giorgino, R., Moro, L., Giustina, A., 2006. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39, 253-259.

Buckley, L., Guyatt, G., Fink, H.A., Cannon, M., Grossman, J., Hansen, K.E., Humphrey, M.B., Lane, N.E., Magrey, M., Miller, M., Morrison, L., Rao, M., Byun Robinson, A., Saha, S., Wolver, S., Bannuru, R.R., Vaysbrot, E., Osani, M., Turgunbaev, M., Miller, A.S., McAlindon, T., 2017. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 69, 1095-1110.

Cohen, S., Levy, R.M., Keller, M., Boling, E., Emkey, R.D., Greenwald, M., Zizic, T.M., Wallach, S., Sewell, K.L., Lukert, B.P., Axelrod, D.W., Chines, A.A., 1999. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42, 2309-2318.

Compston, J., 2018. Glucocorticoid-induced osteoporosis: an update. Endocrine 61, 7-16.

Diez-Perez, A., Adachi, J.D., Agnusdei, D., Bilezikian, J.P., Compston, J.E., Cummings, S.R., Eastell, R., Eriksen, E.F., Gonzalez-Macias, J., Liberman, U.A., Wahl, D.A., Seeman, E., Kanis, J.A., Cooper, C., IOF CSA Inadequate Responders Working Group, 2012. Treatment failure in osteoporosis. Osteoporos. Int. 23, 2769-2774.

Drake, M.T., Clarke, B.L., Khosla, S., 2008. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032-1045.

Eastell, R., Pigott, T., Gossiel, F., Naylor, K.E., Walsh, J.S., Peel, N.F.A., 2018. Diagnosis of endocrine disease: bone turnover markers: are they clinically useful? Eur. J. Endocrinol. 178, R19-R31.

Ebina, K., Hirao, M., Hashimoto, J., Hagihara, K., Kashii, M., Kitaguchi, K., Matsuoka, H., Iwahashi, T., Chijimatsu, R., Yoshikawa, H., 2018. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J. Bone Miner. Metab. 36, 478-487.

Finkelstein, J.S., Wyland, J.J., Lee, H., Neer, R.M., 2010. Effects of teriparatide, alen-dronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 95, 1838-1845.

Hadjidakis, D.J., Androulakis, I.I., 2006. Bone remodeling. Ann. N. Y. Acad. Sci. 1092, 385-396.

Hattori, K., Hirano, Y., 2019. The comparison of the efficacy of switching bispho-sphonates to either denosumab or daily teriparatide osteoporosis in patients with rheumatoid arthritis (in Japanese). Rinsho Riumachi (Clin. Rheumatol. Rel. Res.) 31, 33-40.

Jilka, R.L., 2007. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40, 1434-1446.

Kendler, D.L., Roux, C., Benhamou, C.L.., Brown, J.P., Lillestol, M., Siddhanti, S., Man, H.S., San Martin, J., Bone, H.G., 2010. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone Miner. Res. 25, 72-81.

Laan, R.F., van Riel, P.L., van de Putte, L.B., van Erning, L.J., van't Hof, M.A., Lemmens, J.A., 1993. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann. Intern. Med. 119, 963-968.

Lacey, D.L., Boyle, W.J., Simonet, W.S., Kostenuik, P.J., Dougall, W.C., Sullivan, J.K., San Martin, J., Dansey, R., 2012. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Rev. Drug Discov. 11, 401-419.

Leder, B.Z., Tsai, J.N., Uihlein, A. V., Burnett-Bowie, S.A., Zhu, Y., Foley, K., Lee, H., Neer, R.M., 2014. Two years of Denosumab and teriparatide administration in post-menopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J. Clin. Endocrinol. Metab. 99, 1694-1700.

Martin, T.J., Sims, N.A., 2005. Osteoclast-derived activity in the coupling of bone for- mation to resorption. Trends Mol. Med. 11, 76-81.

Mok, C.C., Ho, L.Y., Ma, K.M., 2015. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 75, 222-228.

Obermayer-Pietsch, B.M., Marin, F., McCloskey, E.V., Hadji, P., Farrerons, J., Boonen, S., Audran, M., Barker, C., Anastasilakis, A.D., Fraser, W.D., Nickelsen, T., 2008. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J. Bone Miner. Res. 23, 1591-1600.

Plotkin, L.I., Bivi, N., Bellido, T., 2011. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone. 49, 122-127.

Reid, D.M., Devogelaer, J.P., Saag, K., Roux, C., Lau, C.S., Reginster, J.Y., Papanastasiou,

P., Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., Sambrook, P.N., HORIZON investigators, 2009. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 373, 1253-1263.

Saag, K.G., Emkey, R., Schnitzer, T.J., Brown, J.P., Hawkins, F., Goemaere, S.,

Thamsborg, G., Liberman, U.A., Delmas, P.D., Malice, M.P., Czachur, M., Daifotis, A.G., 1998. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292-299.

Saag, K.G., Shane, E., Boonen, S., Marín, F., Donley, D.W., Taylor, K.A., Dalsky, G.P., Marcus, R., 2007. Teriparatide or alendronate in glucocorticoid-induced osteo-porosis. N. Engl. J. Med. 357, 2028-2239.

Saag, K.G., Zanchetta, J.R., Devogelaer, J.P., Adler, R.A., Eastell, R., See, K., Krege, J.H., Krohn, K., Warner, M.R., 2009. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of randomized, double-blind, controlled trial. Arthritis Rheumatol. 60, 3346-3355.

Saag, K.G., Pannacciulli, N., Geusens, P., Adachi, J.D., Messina, O.D., Morales-Torres, J., Emkey, R., Butler, P.W., Yin, X., Lems, W.F., 2019. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month rando-mized, double-blind, double-dummy trial. Arthritis Rheumatol. 71, 1174-1184.

Steinbuch, M., Youket, T.E., Cohen, S., 2004. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos. Int. 15, 323-328.

Suzuki, Y., Nawata, H., Soen, S., Fujiwara, S., Nakayama, H., Tanaka, I., Ozono, K.,

Sagawa, A., Takayanagi, R., Tanaka, H., Miki, T., Masunari, N., Tanaka, Y., 2014. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J. Bone Miner. Metab. 32, 337-350.

Suzuki, T., Nakamura, Y., Kato, H., 2018. Significant improvement of bone mineral density by denosumab without bisphosphonate pretreatment in glucocorticoid-in-duced osteoporosis. Mod. Rheumatol. 28, 885-889.

Van Staa, T.P., Laan, R.F., Barton, I.P., Cohen, S., Reid, D.M., Cooper, C., 2003. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224-3229.

Weinstein, R.S., 2011. Glucocorticoid-induced bone disease. N. Engl. J. Med. 365, 62-70.

Weinstein, R.S., Jilka, R.L., Almeida, M., Roberson, P.K., Manolagas, S.C., 2010. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 151, 2641-2649

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る